Do Angiotensin Receptor BLOCKers have beneficial effect on the disease course of COVID-19 infection in high risk or elderly patients in an early phase
- Conditions
- SARS-CoV-2COVID-1910047438
- Registration Number
- NL-OMON50002
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 642
- Age * 70 years of age or comorbidities such as chronic lung disease,
cardiovascular disease, any solid or haematological malignancies, diabetes,
hypertension, rheumatic disease, immune-deficiencies either by disease or by
medication use or severe obesity (BMI * 35).
- Fever (a temperature of * 38,0 °C) or complaints of cough with or without
dyspnoea
- AND at least one of these symptoms typical for SARS-CoV-2 infection such as:
o fatigue
o myalgia
o headache
o nausea, vomiting and diarrhoea
o loss of smell and/or taste.
- Positive PCR test or High suspicion of a SARS-COV-2 infection because of
typical symptoms and the possibility that the individuals could have been
infected.
- Being able to give written or verbal informed consent
- Suffering from (symptomatic) hypotension
- Registered allergy to Telmisartan.
- Receiving Potassium supplement.
- Renal failure requiring dialysis therapy or (previous) kidney transplant
- Known liver disease or liver insufficiency
- Inability to comprehend patient information due to mental impairment such as
dementia.
- life expectancy of less than 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Study endpoints: The primary outcome for this study is a combination of death<br /><br>or hospital admission after 30 days. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary outcomes are time to reduce symptoms, such as fever, cough and<br /><br>dyspnoe after 30 days. </p><br>